Werewolf Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	19.94	16.4	0	0	0
Revenue Growth (YoY)	21.60%	-	-	-	-
Gross Profit	19.94	16.4	0	0	0
Selling, General & Admin	18.67	18.7	14.82	5.76	3.6
Research & Development	41.78	53.76	35.27	16.64	6.34
Operating Expenses	60.45	72.46	50.09	22.4	9.94
Operating Income	-40.5	-56.06	-50.09	-22.4	-9.94
Interest Expense / Income	3.14	0	0	0	0.37
Other Expense / Income	-6.27	-2.25	-0.1	-7.36	-0.06
Pretax Income	-37.37	-53.81	-49.98	-15.04	-10.25
Net Income	-37.37	-53.81	-49.98	-15.04	-10.25
Preferred Dividends	0	0	151.94	13.18	7.98
Net Income Common	-37.37	-53.81	-201.93	-28.22	-18.23
Shares Outstanding (Basic)	36	29	18	1	1
Shares Outstanding (Diluted)	36	29	18	1	1
Shares Change	23.50%	56.40%	1736.32%	57.06%	-
EPS (Basic)	-1.05	-1.86	-10.94	-28.08	-28.49
EPS (Diluted)	-1.05	-1.86	-10.94	-28.08	-28.49
Free Cash Flow	-33.38	-44.21	-43.37	-19.18	-9.81
Free Cash Flow Per Share	-0.94	-1.53	-2.35	-19.09	-15.33
Gross Margin	100.00%	100.00%	-	-	-
Operating Margin	-203.09%	-341.78%	-	-	-
Profit Margin	-187.37%	-328.09%	-	-	-
Free Cash Flow Margin	-167.38%	-269.54%	-	-	-
EBITDA	-30.89	-51.3	-49.25	-14.26	-9.41
EBITDA Margin	-154.89%	-312.79%	-	-	-
Depreciation & Amortization	3.34	2.51	0.74	0.78	0.46
EBIT	-34.23	-53.81	-49.98	-15.04	-9.88
EBIT Margin	-171.63%	-328.09%	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).